MediWound Ltd

NASDAQ:MDWD   10:26:20 AM EDT
3.90
0.00 (0.00%)
Products, Regulatory

Mediwound Announces Positive Topline Results From Phase 3 Pediatric Study (Cids) Of Nexobrid For Eschar Removal Of Severe Thermal Burns

Published: 07/20/2021 13:01 GMT
MediWound Ltd (MDWD) - Mediwound Announces Positive Topline Results From Phase 3 Pediatric Study (cids) of Nexobrid for Eschar Removal of Severe Thermal Burns.
Mediwound Ltd - Study Met Its Three Primary Endpoints With a High Degree of Statistical Significance.
Mediwound Ltd - Nexobrid Demonstrated a Significant Reduction in Time to Achieve Complete Eschar Removal and Significant Reduction in Wound Area Requiring Surgical Excision.
Mediwound Ltd - in Addition, Study Showed That Nexobrid Was Safe and Well-tolerated.